Clinical response and bone marrow MRD status
| Number of patients (%) . | During iFCR (after 3 cycles) . | After iFCR . | After 2-y I-M . |
|---|---|---|---|
| CR with BM-uMRD4 | 9 (10.6) | 28 (32.9) | 29 (34.1) |
| CR with BM-dMRD4 | 6 (7.1) | 2 (2.4) | 10 (11.8) |
| PR with BM-uMRD4 | 31 (36.5) | 40 (47.1) | 10 (11.8) |
| PR with BM-dMRD4 | 28 (32.9) | 11 (12.9) | 1 (1.2) |
| Off study | 1 (1.2) | 3 (3.5) | 11 (12.9) |
| Not assessed | 2 (2.4) | 1 (1.2) | 24 (28.2) |
| Other | 8 (9.4)∗ | 0 | 0 |
| Number of patients (%) . | During iFCR (after 3 cycles) . | After iFCR . | After 2-y I-M . |
|---|---|---|---|
| CR with BM-uMRD4 | 9 (10.6) | 28 (32.9) | 29 (34.1) |
| CR with BM-dMRD4 | 6 (7.1) | 2 (2.4) | 10 (11.8) |
| PR with BM-uMRD4 | 31 (36.5) | 40 (47.1) | 10 (11.8) |
| PR with BM-dMRD4 | 28 (32.9) | 11 (12.9) | 1 (1.2) |
| Off study | 1 (1.2) | 3 (3.5) | 11 (12.9) |
| Not assessed | 2 (2.4) | 1 (1.2) | 24 (28.2) |
| Other | 8 (9.4)∗ | 0 | 0 |
BM-dMRD4, bone marrow detectable MRD; BM-uMRD4, bone marrow undetectable MRD; PR, partial response.
Eight patients discontinued iFCR after 3 cycles and proceeded to ibrutinib maintenance thereafter. Clinical and MRD responses captured after 3 cycles of iFCR were considered as post-iFCR responses.